Institute for Psychedelics and Neurotherapeutics
@ucdavisipn.bsky.social
Our mission is to advance our understanding of the basic neurobiology of psychedelics and translate this knowledge into safe and effective therapeutics
Attend Cure Addiction Now's forum and webinar to hear directly from leading scientists in the field. There are 3 ways to join - in person, online, or on-demand afterwards! To learn more and register, head to this link: cureaddictionnow.org/the-raw-trut...
November 5, 2025 at 5:38 PM
Attend Cure Addiction Now's forum and webinar to hear directly from leading scientists in the field. There are 3 ways to join - in person, online, or on-demand afterwards! To learn more and register, head to this link: cureaddictionnow.org/the-raw-trut...
We shared earlier this year that zalsupindole, a non-hallucinogenic psychedelic analogue created at @UC Davis by #UCDavisIPN Director @deolsonlab.bsky.social and his team, entered phase1B clinical trials. We are now thrilled to share the results!!
www.businesswire.com
October 28, 2025 at 3:11 PM
We shared earlier this year that zalsupindole, a non-hallucinogenic psychedelic analogue created at @UC Davis by #UCDavisIPN Director @deolsonlab.bsky.social and his team, entered phase1B clinical trials. We are now thrilled to share the results!!
Check out #UCDavisIPN affiliate @manvir.bsky.social on the debut episode of the @mindsovermatters.bsky.social podcast. He explores shamanism’s deep roots across cultures and how various aspects have echoed through modern societies.
We're kicking things off with evolutionary anthropologist Dr. Manvir Singh for a fascinating conversation about a phenomenon that repeatedly appears across human cultures: shamanism. But why is this the case? What is shamanism? Why does it repeatedly develop across societies? Join us to find out.
Seeing Shamanism Everywhere
YouTube video by Minds Over Matters
youtu.be
October 16, 2025 at 8:16 PM
Check out #UCDavisIPN affiliate @manvir.bsky.social on the debut episode of the @mindsovermatters.bsky.social podcast. He explores shamanism’s deep roots across cultures and how various aspects have echoed through modern societies.
Read the latest research from Delix on #zalsupindole, a compound invented at the #UCDavisIPN by director @deolsonlab.bsky.social and his team. Zalsupindole, is a non-dissociative, non-hallucinogenic #psychedelic analogue, and is the first neuroplastogen to be administered to patients with MDD!
Zalsupindole is a Nondissociative, Nonhallucinogenic Neuroplastogen with Therapeutic Effects Comparable to Ketamine and Psychedelics
Many neuropsychiatric conditions, including depression, involve synaptic loss and atrophy of the prefrontal cortex. The rapid regrowth of cortical neurons has been hypothesized to explain the rapid an...
pubs.acs.org
October 14, 2025 at 3:17 PM
Read the latest research from Delix on #zalsupindole, a compound invented at the #UCDavisIPN by director @deolsonlab.bsky.social and his team. Zalsupindole, is a non-dissociative, non-hallucinogenic #psychedelic analogue, and is the first neuroplastogen to be administered to patients with MDD!
#UCDavisIPN Director @deolsonlab.bsky.social and his team studied mice without INMT, an enzyme long thought to be essential for producing endogenous #psychedelics like DMT. The surprise...?
October 2, 2025 at 7:54 PM
#UCDavisIPN Director @deolsonlab.bsky.social and his team studied mice without INMT, an enzyme long thought to be essential for producing endogenous #psychedelics like DMT. The surprise...?
In a new publication from #UCDavisIPN affiliate Danielle Stolzenberg, her team found that postpartum mice given psilocybin showed a long-term increase in anxiety behaviors after a single dose. Even more striking, their offspring experienced similar effects.
Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring - Nature Communications
The treatment potential of psilocybin for postpartum depression was investigated in a preclinical mouse model. Here the authors show both acute and long-term effects of psilocybin in mothers and their offspring who were exposed via lactation.
www.nature.com
September 30, 2025 at 3:06 PM
In a new publication from #UCDavisIPN affiliate Danielle Stolzenberg, her team found that postpartum mice given psilocybin showed a long-term increase in anxiety behaviors after a single dose. Even more striking, their offspring experienced similar effects.
Researchers @umich.edu found #psychedelics can boost brain connections even when neurons don’t have the usual 5-HT2A receptor because nearby cells pass the effect along. At #UCDavisIPN, we’re also exploring surprising ways psychedelics reshape the brain.
Psychedelic neuroplasticity of cortical neurons lacking 5-HT2A receptors - Molecular Psychiatry
Molecular Psychiatry - Psychedelic neuroplasticity of cortical neurons lacking 5-HT2A receptors
www.nature.com
September 24, 2025 at 4:19 PM
Researchers @umich.edu found #psychedelics can boost brain connections even when neurons don’t have the usual 5-HT2A receptor because nearby cells pass the effect along. At #UCDavisIPN, we’re also exploring surprising ways psychedelics reshape the brain.
Interested in reading more about the IPN? Join our newsletter! We publish each Spring and Fall. We share about our research of course, but you can also get an inside look at what we're all about here at the #UCDavisIPN. Sign up here:
UC Davis Institute for Psychedelics & Neurotherapeutics Newsletter
Sign up for our newsletter:
docs.google.com
September 19, 2025 at 5:38 PM
Interested in reading more about the IPN? Join our newsletter! We publish each Spring and Fall. We share about our research of course, but you can also get an inside look at what we're all about here at the #UCDavisIPN. Sign up here:
IPN collaborator Dr. Uri Manor at
@ucsandiego.bsky.social reveals that #psychedelics as well as non-hallucinogenic analogues developed at the #UCDavisIPN can grow new synapses in the cochlea of mice which could open new horizons for treating age-related hearing loss.
@ucsandiego.bsky.social reveals that #psychedelics as well as non-hallucinogenic analogues developed at the #UCDavisIPN can grow new synapses in the cochlea of mice which could open new horizons for treating age-related hearing loss.
Scientists find psychedelics stimulate the growth of new synapses in the ear
Scientists are exploring the possibilities
spectrumnews1.com
September 10, 2025 at 2:56 PM
IPN collaborator Dr. Uri Manor at
@ucsandiego.bsky.social reveals that #psychedelics as well as non-hallucinogenic analogues developed at the #UCDavisIPN can grow new synapses in the cochlea of mice which could open new horizons for treating age-related hearing loss.
@ucsandiego.bsky.social reveals that #psychedelics as well as non-hallucinogenic analogues developed at the #UCDavisIPN can grow new synapses in the cochlea of mice which could open new horizons for treating age-related hearing loss.
New in @jama.com: A phase 2b trial of an oral LSD formulation (MM120) found that 100 µg and 200 µg doses significantly reduced anxiety symptoms in adults with generalized anxiety disorder. Results support 100 µg as the optimal dose for future trials.
Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder
This randomized clinical trial assesses the dose-response relationship of MM120 (lysergide D-tartrate) vs placebo in adults with moderate to severe generalized anxiety disorder.
jamanetwork.com
September 9, 2025 at 5:01 PM
New in @jama.com: A phase 2b trial of an oral LSD formulation (MM120) found that 100 µg and 200 µg doses significantly reduced anxiety symptoms in adults with generalized anxiety disorder. Results support 100 µg as the optimal dose for future trials.
Reunion Neuroscience has achieved positive topline results from the Phase 2 trial of RE104, a synthetic #psychedelic, in postpartum depression. This marks an exciting milestone for their mission. Remarkably, 71% of patients experienced remission of symptoms within 7 days.
Reunion Neuroscience Announces Positive Topline Results from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)
-- Achieved Primary Endpoint with 30mg Dose of RE104 Demonstrating 23.0-Point Reduction from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS)...
www.globenewswire.com
August 18, 2025 at 8:20 PM
Reunion Neuroscience has achieved positive topline results from the Phase 2 trial of RE104, a synthetic #psychedelic, in postpartum depression. This marks an exciting milestone for their mission. Remarkably, 71% of patients experienced remission of symptoms within 7 days.
On @npr.org’s The Sunday Story, IPN Director, @deolsonlab.bsky.social explains how #psychedelics may treat depression by promoting brain plasticity and why he’s working to engineer out the trip.
🎧 Hear more on the psychedelic renaissance and where science is headed:
🎧 Hear more on the psychedelic renaissance and where science is headed:
Can Psychedelic Therapy Go Mainstream? : Up First from NPR
Research shows that psychedelics can help with a range of mental health conditions, like PTSD and depression. So why can't you get them from your doctor? Today on The Sunday Story, we take a trip thro...
www.npr.org
August 6, 2025 at 5:54 PM
On @npr.org’s The Sunday Story, IPN Director, @deolsonlab.bsky.social explains how #psychedelics may treat depression by promoting brain plasticity and why he’s working to engineer out the trip.
🎧 Hear more on the psychedelic renaissance and where science is headed:
🎧 Hear more on the psychedelic renaissance and where science is headed:
Greg Watry of @ucdlands.bsky.social wrote a wonderful article about the #UCDavisIPN's @natureportfolio.nature.com most recent Neuroscience publication. Find out why our associate director, John A. Gray said, "Science is full of surprises."
Read the article here: www.ucdavis.edu/news/psyched...
Read the article here: www.ucdavis.edu/news/psyched...
Psychedelics and Non-hallucinogenic Analogs Work Through the Same Receptor, Up to a Point
Understanding exactly how psychedelics promote new connections in the brain is critical to developing targeted, non-hallucinogenic therapeutics that can treat neurodegenerative and neuropsychiatric di...
www.ucdavis.edu
August 5, 2025 at 3:44 PM
Greg Watry of @ucdlands.bsky.social wrote a wonderful article about the #UCDavisIPN's @natureportfolio.nature.com most recent Neuroscience publication. Find out why our associate director, John A. Gray said, "Science is full of surprises."
Read the article here: www.ucdavis.edu/news/psyched...
Read the article here: www.ucdavis.edu/news/psyched...
The field of psychedelic science is finally closer to an answer on how non-hallucinogenic psychedelic analogues induce neuroplasticity. Read the new publication from the #UCDavisIPN in @natureportfolio.nature.com Neuroscience about how the team uncovered this using TBG, lasers, and genetic tools.
The psychoplastogen tabernanthalog induces neuroplasticity without proximate immediate early gene activation - Nature Neuroscience
Aarrestad et al. show that, in contrast to psychedelics, the nonhallucinogenic psychoplastogen tabernanthalog promotes neuroplasticity through 5-HT2AR activation without immediately increasing extrace...
www.nature.com
August 4, 2025 at 3:21 PM
The field of psychedelic science is finally closer to an answer on how non-hallucinogenic psychedelic analogues induce neuroplasticity. Read the new publication from the #UCDavisIPN in @natureportfolio.nature.com Neuroscience about how the team uncovered this using TBG, lasers, and genetic tools.
#UCDavisIPN Director @deolsonlab.bsky.social spoke with Lisa Wexler from the Voice of Connecticut about JRT, a non-hallucinogenic #psychedelic analogue with potential to treat schizophrenia.
🔗 Listen to David's segment on The Lisa Wexler Show here or anywhere you get your podcasts:
🔗 Listen to David's segment on The Lisa Wexler Show here or anywhere you get your podcasts:
A New Drug Could Revolutionize Treating Mental Health | The Lisa Wexler Show
shows.acast.com
July 22, 2025 at 8:29 PM
#UCDavisIPN Director @deolsonlab.bsky.social spoke with Lisa Wexler from the Voice of Connecticut about JRT, a non-hallucinogenic #psychedelic analogue with potential to treat schizophrenia.
🔗 Listen to David's segment on The Lisa Wexler Show here or anywhere you get your podcasts:
🔗 Listen to David's segment on The Lisa Wexler Show here or anywhere you get your podcasts:
A team led by @zenbrainest.bsky.social and colleagues screened 41 classical #psychedelics across 318 human receptors. The result? A sweeping map of psychedelic polypharmacology that includes broad activity at serotonin, dopamine, and adrenergic receptors.
🔗 Read the full study:
🔗 Read the full study:
The polypharmacology of psychedelics reveals multiple targets for potential therapeutics
Jain et al. profiled 41 classical psychedelics across 318 GPCRs, revealing activity
at serotonin, dopamine, and adrenergic receptors. All compounds activated multiple
5-HT2AR signal transduction pathw...
www.cell.com
July 21, 2025 at 4:29 PM
A team led by @zenbrainest.bsky.social and colleagues screened 41 classical #psychedelics across 318 human receptors. The result? A sweeping map of psychedelic polypharmacology that includes broad activity at serotonin, dopamine, and adrenergic receptors.
🔗 Read the full study:
🔗 Read the full study:
Big news in #psychedelic science: Compass Pathways' proprietary psilocybin formulation is the first-ever classic psychedelic in a Phase 3 trial. It showed a significant reduction in depression symptoms compared to placebo. We’re very excited to see the data once published!
Read the press release:
Read the press release:
Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the succe...
www.businesswire.com
June 24, 2025 at 8:18 PM
Big news in #psychedelic science: Compass Pathways' proprietary psilocybin formulation is the first-ever classic psychedelic in a Phase 3 trial. It showed a significant reduction in depression symptoms compared to placebo. We’re very excited to see the data once published!
Read the press release:
Read the press release:
#UCDavisIPN Affiliate @sadeghlab.bsky.social co-authored a new @natureportfolio.nature.com paper revealing how maternal exposure to 5-HT2C agonists can cause the choroid plexus to secrete proteins into cerebrospinal fluid, affecting fetal brain development and behavior into adulthood. Read more:
Choroid plexus apocrine secretion shapes CSF proteome during mouse brain development - PubMed
The choroid plexus (ChP) regulates cerebrospinal fluid (CSF) composition, providing essential molecular cues for brain development; yet, embryonic ChP secretory mechanisms remain poorly defined. Here ...
pubmed.ncbi.nlm.nih.gov
June 16, 2025 at 8:44 PM
#UCDavisIPN Affiliate @sadeghlab.bsky.social co-authored a new @natureportfolio.nature.com paper revealing how maternal exposure to 5-HT2C agonists can cause the choroid plexus to secrete proteins into cerebrospinal fluid, affecting fetal brain development and behavior into adulthood. Read more:
Meet us at the Davis Public Library in Davis on May 29th for IPN Affiliate @manvir.bsky.social's author talk on "Shamanism: The Timeless Religion." Register for the event, hosted by the Avid Reader, using the link below.
Where: 315 E. 14th Street, Davis, CA 95616
Time: 6:30PM
#shamanism #UCDavisIPN
Where: 315 E. 14th Street, Davis, CA 95616
Time: 6:30PM
#shamanism #UCDavisIPN
Manvir Singh @ The Yolo County Library
Davis' Local Independent Bookstore since 1987
avidreaderbooks.com
May 23, 2025 at 3:32 PM
Meet us at the Davis Public Library in Davis on May 29th for IPN Affiliate @manvir.bsky.social's author talk on "Shamanism: The Timeless Religion." Register for the event, hosted by the Avid Reader, using the link below.
Where: 315 E. 14th Street, Davis, CA 95616
Time: 6:30PM
#shamanism #UCDavisIPN
Where: 315 E. 14th Street, Davis, CA 95616
Time: 6:30PM
#shamanism #UCDavisIPN
Now available: Shamanism: The Timeless Religion written by IPN Affiliate @manvir.bsky.social. Manvir's work cuts through myths and binaries, exploring the deeper meaning behind our fascination with shamanism and ancient ways of knowing.
Order your copy now:
#UCDavisIPN #shamanism
Order your copy now:
#UCDavisIPN #shamanism
Shamanism by Manvir Singh: 9780593537541 | PenguinRandomHouse.com: Books
From a brilliant, young, Harvard-trained anthropologist and contributor to The New Yorker comes a fascinating investigation into the spiritual practice of shamanism, from its beginnings to the present...
www.penguinrandomhouse.com
May 20, 2025 at 6:50 PM
Now available: Shamanism: The Timeless Religion written by IPN Affiliate @manvir.bsky.social. Manvir's work cuts through myths and binaries, exploring the deeper meaning behind our fascination with shamanism and ancient ways of knowing.
Order your copy now:
#UCDavisIPN #shamanism
Order your copy now:
#UCDavisIPN #shamanism
IPN Affiliate @manvir.bsky.social's new book "Shamanism: The Timeless Religion" releases May 20th. The book is a provocative journey through history, belief, and the incredible diversity of human spiritual and healing practices.
May 16, 2025 at 6:46 PM
IPN Affiliate @manvir.bsky.social's new book "Shamanism: The Timeless Religion" releases May 20th. The book is a provocative journey through history, belief, and the incredible diversity of human spiritual and healing practices.
Thanks to NIH Research Matters team for recognizing the #UCDavisIPN's work on JRT. This work brings us closer to creating effective and practical treatments for patients.
An LSD analogue for treating psychiatric diseases
Researchers designed a non-hallucinogenic analogue of LSD that had antidepressant and numerous cognitive benefits in mice.
www.nih.gov
May 7, 2025 at 9:00 PM
Thanks to NIH Research Matters team for recognizing the #UCDavisIPN's work on JRT. This work brings us closer to creating effective and practical treatments for patients.
Fascinating read by IPN affiliate @manvir.bsky.social in @theguardian.com on how stories about “ancient” psychedelic use are often shaped by what tourists want to hear, not necessarily what’s true. This is a must-read for anyone thinking about tradition, authenticity, and modern #psychedelics.
The ancient psychedelics myth: ‘People tell tourists the stories they think are interesting for them’
The narrative of ancient tribes around the world regularly using ayahuasca and magic mushrooms in healing practices is a popular one. Is it true?
www.theguardian.com
May 6, 2025 at 5:27 PM
Fascinating read by IPN affiliate @manvir.bsky.social in @theguardian.com on how stories about “ancient” psychedelic use are often shaped by what tourists want to hear, not necessarily what’s true. This is a must-read for anyone thinking about tradition, authenticity, and modern #psychedelics.
Check out this write-up on JRT, an LSD analogue created at the #UCDavisIPN published last week in @pnas.org. Thanks to BBRF for highlighting our research on how swapping just two atoms could change how schizophrenia is treated. Read more about our latest study here:
Modifying LSD to Minimize Hallucinogenic Properties Results in a Potential New Drug Candidate for Schizophrenia | Brain & Behavior Research Foundation
Some psychedelic compounds have been shown to be powerful promoters of growth in atrophied cortical neurons, a fact that has intrigued researchers interested in addressing one of the hallmark patholog...
bbrfoundation.org
April 24, 2025 at 10:43 PM
Check out this write-up on JRT, an LSD analogue created at the #UCDavisIPN published last week in @pnas.org. Thanks to BBRF for highlighting our research on how swapping just two atoms could change how schizophrenia is treated. Read more about our latest study here:
Thank you, Greg Watry, for this write-up on JRT, our non-hallucinogenic LSD analog from the #UCDavisIPN. This compound has the potential to treat patients affected by schizophrenia! @ucdavismedschool.bsky.social @ucdlands.bsky.social @ucdaviscns.bsky.social
A new frontier in neuropsychiatric treatment.
@ucdavis.bsky.social researchers at @ucdavisipn.bsky.social have engineered a safer LSD-inspired compound called JRT, which maintains powerful neuroplastic effects while reducing hallucinogenic risk.
@ucdavis.bsky.social researchers at @ucdavisipn.bsky.social have engineered a safer LSD-inspired compound called JRT, which maintains powerful neuroplastic effects while reducing hallucinogenic risk.
Researchers Develop an LSD Analogue with Potential for Treating Schizophrenia
University of California, Davis, researchers have developed a new, neuroplasticity-promoting drug closely related to LSD that harnesses the psychedelic’s therapeutic power with reduced hallucinogenic ...
lettersandsciencemag.ucdavis.edu
April 15, 2025 at 3:38 PM
Thank you, Greg Watry, for this write-up on JRT, our non-hallucinogenic LSD analog from the #UCDavisIPN. This compound has the potential to treat patients affected by schizophrenia! @ucdavismedschool.bsky.social @ucdlands.bsky.social @ucdaviscns.bsky.social